PHASE I/II TRIAL OF R115777 AND XRT IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSE

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 摘要 假设 法尼基转移酶抑制剂R115777将在脑干神经胶质瘤患者中作为放射增敏剂发挥作用。 此外，R115777治疗后，在脑干胶质瘤中观察到ras介导的抗肿瘤活性。 具体目标 主要目标 1. 估计R115777在非播散性、弥漫性、原发性脑干神经胶质瘤儿科患者中同时接受有限剂量递增放疗时的MTD。 2. 通过无进展生存期评估R115777联合放疗治疗非播散性、弥漫性、内源性脑桥胶质瘤患者的疗效。 次要目的 3. 描述与R115777联合放射治疗相关的毒性。 4. 使用MRI、MRS、灌注和弥散成像以及PET扫描表征接受放疗和R115777治疗的脑干胶质瘤的影像学变化。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. ABSTRACT HYPOTHESES The farnesyltransferase inhibitor, R115777, will function as a radiosensitizing agent in patients with brainstem gliomas. In addition, ras-mediated anti-tumor activity will be observed in brainstem gliomas following treatment with R115777. SPECIFIC AIMS Primary Objectives 1. To estimate the MTD of R115777 when administered to pediatric patients with nondisseminated, diffuse, intrinisc brainstem gliomas concurrently with radiation therapy with a limited dose escalation. 2. To assess the efficacy of R115777 treatment in combination with radiation therapy for patients with non-dissemianted, diffuse, intrinsic pontine gliomas as measured by progression-free survival. Secondary Objectives 3. To characterize toxicities associated with R115777 in combination with radiation therapy. 4. To characterize radiographic changes in brainstem gliomas treated with radiation and R115777 using MRI, MRS, perfusion and diffusion imaging and PET scans.